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Summary
A key strategy to protect humans against an influenza
pandemic is the development of an effective vaccine.
However, the development of effective pandemic vac-
cines poses both practical and immunological chal-
lenges.
Introduction
Influenza viruses cause repeated infections in humans
and are a significant cause of morbidity and mortality
annually; they account for as many as 36,000 excess
deaths each winter in the United States (Thompson
et al., 2003; Wright and Webster, 2001). Influenza is a
winter illness in temperate climates; however, it occurs
in two peaks or throughout the year in tropical climates.
Three types of influenza viruses, designated influenza A,
B, and C, are present in nature, and of these, influenza A
and B viruses cause annual epidemics. Humans are the
only hosts for influenza B viruses, but influenza A viruses
infect a variety of species, including birds, pigs, horses,
dogs, and humans (Wright and Webster, 2001; Crawford
et al., 2005). Influenza A viruses, but not influenza B or
C viruses, are divided into subtypes based on the anti-
genicity of the two major surface glycoproteins, the
hemagglutinin (HA) and neuraminidase (NA). These two
proteins are the main targets of the protective immune
response. The HA is a trimer with a receptor binding
pocket on the globular head of each monomer, and the
NA is a tetramer with an enzyme active site on the head
of each monomer.
Aquatic birds represent the reservoir of influenza A
viruses in nature. Viruses of all known (16 HA and 9 NA)
subtypes have been isolated from waterfowl and shore-
birds. However, influenza infections in waterfowl tend
to be asymptomatic, and the viruses are in ecological
stasis in these hosts (Webster et al., 1992). In contrast,
influenza A virus infections in humans elicit an immune
response that provides selective pressure and drives
the virus to evolve. Influenza viruses utilize two mecha-
nisms, referred to as antigenic drift and antigenic shift,
to evade the human immune response. Antigenic drift
is a continuous process of change in which mutations
occur in and around the antibody (Ab)-recognition sites
of the HA and NA proteins; these recognition sites allow
the virus to escape neutralization by pre-existing Abs.
Five Ab-combining sites have been mapped on the HA
of H3 subtype human influenza A viruses (Wilson and
Cox, 1990); however, less is known about HAs of avian
influenza A subtypes. Antigenic shift is a rare but epide-
*Correspondence: afauci@niaid.nih.govmiologically highly significant event in which a virus
bearing a novel HA, with or without an accompanying
novel NA, is introduced into the human population. A
virus bearing a novel HA or NA has the potential to cause
a pandemic if a large proportion of the population lacks
immunity to the novel HA and NA and if the virus has the
ability to spread efficiently from person to person. The
novel HA and NA genes in pandemic influenza viruses
are derived from the reservoir of avian influenza viruses
in nature.
Pre-Existing Immunity against Influenza
During an influenza-virus infection, HA- or NA-specific
Abs present at systemic or mucosal sites are the major
mediators of resistance to the virus, whereas the cellular
immune response to influenza works with the humoral
immune response in viral clearance (Murphy and Cha-
nock, 2001) (Figure 1). Abs directed at the HA and NA
surface glycoproteins of the virus are effective in medi-
ating protection that is long-lived in the absence of anti-
genic drift or shift. This was evident in 1977 when an
H1N1 virus that had circulated in the early 1950s reap-
peared in the human population. Significant disease was
only seen in persons born after the H1N1 virus had
stopped circulating in 1957, indicating that homotypic
immunity is long-lived. Because individuals born after
1957 were infected multiple times with H2N2 or H3N2
viruses that share internal protein antigens (e.g., nucleo-
protein) with the H1N1 virus, it was clear that cell-
mediated immunity to shared antigens, such as the nu-
cleoprotein, played a relatively small role in resistance.
Thus, homotypic Abs are highly protective and mediate
significant protection in humans, whereas Abs to the HA
and NA of other subtypes and cell-mediated immune
responses are less effective in long-term immunity.
Heterosubtypic immunity, which is protection con-
ferred by previous infection(s) with an influenza virus
of a different subtype, is weak in humans, especially in
children. Recent analysis of epidemiological data col-
lected before and during the 1957 pandemic suggests
that heterosubtypic immunity was observed in adults but
not in children (Epstein, 2006). However, definitive data
regarding the role that heterosubtypic immunity plays
in resistance to influenza-virus infection in humans are
lacking, and the mediators of such immunity in humans
have not been identified.
An analysis of genetic and antigenic data on the HA
from human influenza A H3N2 viruses led to the conclu-
sions that the HA was under positive selection (Fitch
et al., 1997) and that two or more amino acid changes
in two or more Ab combining sites of the HA were suffi-
cient for a virus to evade neutralization by Ab against
the previously circulating strain (Wilson and Cox, 1990).
Cellular immunity is directed at epitopes on several
influenza-virus proteins, but this immunity is relatively
short-lived (Murphy and Chanock, 2001).
Vaccine Development
Several important considerations for vaccine devel-
opment follow from our knowledge of the interactions
between influenza viruses and the host. First, influenza
viruses replicate extremely rapidly in the host. Peak
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6Figure 1. Life Cycle of Influenza Virus and Role of the Adaptive Immune Response during Infection
Influenza virus attaches to the epithelial cell surface through binding of the viral hemagglutinin (HA) protein to cell surface sialic acid receptors
(1, 2). The virion is internalized through endocytosis and fusion (3). Opening of the M2 channel allows proton flow across the viral membrane
(4), triggering fusion of viral and endosomal membranes and release of viral genes into the cytoplasm, from where they travel to the nucleus.
Viral proteins produced in cytoplasm assemble with viral genes and bud from the cell membrane as progeny virions (5). Release of new virus
particles (6) requires the viral neuraminidase (NA) protein, which cleaves sialic acid receptors from the cell membrane. Antibodies (Abs) to
the HA protein block virus attachment (inset, upper left), thereby decreasing the number of cells infected. They can also function to prevent fusion
(4). Abs to the NA protein (inset, upper right) bind virus to the cell, preventing release of new virions. Abs to the M2 protein bind virus to the cell and
prevent release of viral particles into the extracellular fluid (inset, lower left). Cell-mediated immunity contributes to resistance when CD8+ T cells
specific for viral proteins such as nucleoprotein (NP) or polymerase proteins (PB2 and PA) recognize viral peptides presented by MHC class I
proteins, resulting in the release of cytokines with antiviral activity (IFN-g and TNF-a) and perforins that mediate cytolysis of the infected cell (in-
set, lower right). Lysis of the infected cell decreases the amount of virus released by the cell. The latter three mechanisms, NA Abs, M2 Abs, and
CD8+ T cells, operate after a cell becomes infected. Only HA Abs prevent infection; this is likely to be why they are the most effective in vivo.titers (which correlate with disease) are achieved before
a cell-mediated immune response can be generated de
novo or from memory to restrict replication (Figure 2).
Therefore, the major goal of the currently licensed influ-
enza vaccines is to induce, prior to infection, Abs that
function to dampen virus replication. Second, influenza
is a respiratory-tract infection, and Abs induced by vac-
cine that restrict replication throughout the upper and
lower respiratory tract are desired. Intranasally adminis-
tered live, attenuated vaccines efficiently induce a mu-
cosal as well as a systemic Ab response. Mucosal Abs
are more effective than systemic Abs in restricting repli-
cation of influenza virus in the upper respiratory tract. In
contrast, parenterally administered inactivated vaccines
primarily induce systemic (serum) Abs that restrict repli-cation of virus in the lower respiratory tract. Therefore,
inactivated vaccines are effective in prevention of se-
vere disease and complications of influenza but are less
effective than previous natural infection and live, attenu-
ated virus vaccine in protection of the upper respiratory
tract. Third, the ability of the virus to drift and evade im-
mune detection and the paucity of HA conserved epi-
topes that induce cross-reactive neutralizing or protec-
tive Abs pose a challenge for vaccine development.
Currently licensed human influenza vaccines are up-
dated annually to keep up with antigenic drift that is
identified through virologic surveillance. Fourth, clinical
studies have established that two doses of currently for-
mulated inactivated vaccine are required to elicit protec-
tive Ab titers in immunologically naı¨ve individuals. The
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7Figure 2. Course of Immune Response dur-
ing Influenza Infection
Influenza virus titers peak at approximately 3
days after infection, at which time antibodies
(Abs) and T cell responses begin to appear.
Activated T cell responses peak on days 6–9
during the primary infection and then sub-
side into a memory or resting state, whereas
serum and mucosal Ab concentrations are
sustained. Abs present at the time of reinfec-
tion result in lower viral titers and a reduction
in symptoms. Upper respiratory infection,
URI, lower respiratory infection, LRI.live, attenuated virus vaccine is significantly more immu-
nogenic than inactivated virus vaccine in naı¨ve individ-
uals. In practical terms, each winter, previously unimmu-
nized children should receive two doses of vaccine one
month apart, whereas a single vaccine dose can protect
previously primed children and adults.
Pandemic Influenza Preparedness
Recent events in Asia have highlighted the pandemic
potential of avian influenza viruses and the need to pre-
pare for an antigenic shift in influenza A viruses. Al-
though antiviral drugs can be effective in prophylaxis,
vaccines are the preferred strategy for the prevention
of a pandemic because pandemic viruses might be re-
sistant to available antiviral drugs or, even if initially sen-
sitive, can rapidly develop drug resistance (Le et al.,
2005; de Jong et al., 2005). A realistic goal of a pandemic
influenza vaccine is to prevent mortality and severe mor-
bidity with acceptance of the fact that infections associ-
ated with mild illness will not be prevented. This requires
the development of vaccines that, at the least, elicit sys-
temic Abs of sufficient titer to restrict virus replication in
the lower respiratory tract and thereby prevent pneumo-
nia and its associated complications.
Although principles that have been established from
basic and applied research in human influenza can be
applied to pandemic influenza vaccine development,
several critical gaps in knowledge remain. For example,
the antigenic sites on avian HAs and the immune corre-
lates of protection from avian influenza-virus infections
are not known. Additionally, the HA proteins of avian
subtypes of influenza A viruses are not as immunogenic
as human influenza A HA subtypes for unknown rea-
sons; therefore, approaches to enhance the immunoge-
nicity of the avian HA in a pandemic virus may be needed
to achieve a protective level of immunity. Such new ap-
proaches will be needed in addition to the two doses of
vaccine now required to successfully immunize a naı¨ve
population.
Currently, two classes of vaccines are licensed for in-
terpandemic influenza in the US: parenterally delivered
inactivated virus vaccines (whole virus or subunit) and
a live, attenuated vaccine delivered as a nasal spray.
Both types of vaccines are trivalent and contain an influ-
enza A H1N1 subtype virus, an influenza A H3N2 subtype
virus, and an influenza B virus to protect against each ofthe co-circulating strains of influenza. Vaccines against
potential pandemic strains of influenza are now being
developed based on both of these strategies. Seed vi-
ruses for inactivated vaccines have been generated
against influenza viruses of H5, H7, and H9 subtypes.
Preclinical data have been generated for all three sub-
types, and H5 and H9 subtype vaccines have been
evaluated in phase I clinical trials (Hehme et al., 2002;
Nicholson et al., 2001; Stephenson et al., 2003). The in-
vestigational H5 and H9 inactivated vaccines are less
immunogenic than interpandemic influenza vaccines
(H1 and H3 subtypes). The amount of HA required in
pandemic vaccines to elicit a serum Ab response of a
magnitude similar to that of the licensed interpandemic
influenza vaccine is likely to exceed the 15 mg present in
the current inactivated virus vaccines. This increase
in dose will determine the number of doses of vaccine
available in the event of a pandemic and could strain
manufacturing capacity.
In addition to seed viruses being made beforehand
and their safety and immunogenicity being evaluated,
several important applied vaccine research issues
should be explored to ensure the availability of enough
doses of appropriately immunogenic influenza vaccines
to protect the population against potential pandemic
strains of influenza. These include an exploration of ways
to reduce the amount of HA antigen required to elicit
protective Ab titers by investigation of alternative routes
of vaccine administration; use of known and novel adju-
vants to enhance immunogenicity; and consideration of
a strategy of pre-emptive vaccination to prime the pop-
ulation for an Ab response to a novel HA. Preliminary re-
sults from a phase I clinical trial indicate that inactivated
H9N2 vaccine administered with adjuvant is significantly
more immunogenic than vaccine without adjuvant.
Efforts are under way to develop and evaluate live,
attenuated vaccines against potential pandemic strains
of influenza along a track that parallels the development
and evaluation of inactivated virus vaccines (Luke and
Subbarao, 2006). The live, attenuated pandemic-influ-
enza vaccine candidates contain the attenuating genes
of the A/Ann Arbor/6/60 cold-adapted virus that is the
backbone of the licensed live, attenuated influenza A
virus vaccine. Candidate vaccines have been generated
against H5 and H9 subtype viruses, and vaccines
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data are obtained from preclinical testing, these vac-
cines will be evaluated in phase I clinical trials for safety,
infectivity, and immunogenicity. As in the case of inacti-
vated vaccines, cell culture substrates should be evalu-
ated as alternatives to embryonated eggs for vaccine
manufacture.
Harnessing Immunological Memory
Several decades of experience with human influenza
vaccines indicates that the vaccine strain must be
closely related to the epidemic strain of influenza in order
to be effective. Although the match between vaccine
virus strains and epidemic virus strains is generally good
because the evolution of human influenza viruses is con-
tinuously monitored through careful, global virologic
surveillance and vaccine strains are updated based on
these data, wehave no basisupon which topredict which
exact strain of avian influenza will cross the species bar-
rier and cause a pandemic. This makes it unlikely that the
vaccine strain will exactly match the pandemic strain.
A vaccine that provides cross-reactive immunity among
the H1–H16 subtypes of influenza would be preferable.
Further research and development efforts are required
to achieve this goal.
The development of cross-subtype, HA-based pro-
tection requires the identification of conserved H1–H16
HA sites that could induce broadly protective, highly
functional neutralizing Abs. It is important to emphasize
that such Abs are not regularly induced in humans by in-
fection with influenza A viruses belonging to multiple HA
subtypes, an observation that indicates the difficulty of
achieving this goal. A recent advance in this area is the
determination of the crystal structures of the HA from
several additional subtypes of influenza A viruses. The
first 15 HA subtypes fall into four clades (two groups of
two), with H1, H3, H7, and H9 being the prototypes of
the four clades (Russell et al., 2004.) Perhaps the com-
monalities within clades of HA subtypes based on HA
structure can be exploited to develop immunogens and
strategies that can induce cross-reactive Abs effective
among HA subtypes. Another approach to inducing
broadly cross-protective immunity involves identifying
conserved CD8+ T cell epitopes (Figure 1) that can be in-
duced in most members of the population and maintain-
ing the CD8+ T cells in a highly functional state that can
keep an infecting influenza virus from reaching high titer
in vivo. This second point represents a real challenge be-
cause the genetic program of the CD8+ T cell response is
to transform cells from an inactive memory state into an
activated state, and maintaining CD8+ T cells in an acti-
vated state will have to happen in the absence of anti-
genic stimulus. The immunogens capable of inducing
this type of response have yet to be identified but could
include sequences from circulating H1 and H3 subtype
influenza viruses. Immunization with such T cell vac-
cines could provide varying degrees of resistance to dis-
ease after infection with an H5N1 pandemic virus, as
well as with circulating H1 and H3 viruses. It is essential
to determine the ability to maintain this state of immunity
throughout the period of circulation of the first wave of
the pandemic virus. The M2 protein of influenza A vi-
ruses forms a proton channel in the virion and intracellu-
lar membrane and functions to release influenza virus
genes from endosomes (Figure 1, step 4). It is highlyconserved, and non-neutralizing Abs to the M2 protein
protect mice from subsequent challenge (Figure 1)
(Treanor et al., 1990; Neirynck et al., 1999). Clinical stud-
ies can be designed to determine whether the induction
of M2 Abs prevents disease in humans. If so, efforts can
be undertaken to evaluate whether a more robust and
protective M2 Ab response can be achieved by immuni-
zation than by repeated infection in nature. Presentation
of the M2 protein to the immune system in a more immu-
nogenic form via vaccination than occurs in natural in-
fection may be important in this regard.
In conclusion, two approaches to the development of
vaccines for pandemic preparedness can be exploited.
The first and more immediately accessible uses existing
technology to generate vaccines that induce highly func-
tional and protective Abs. Efforts in this area should
focus on pre-emptive preparation of vaccine seed vi-
ruses and evaluation of their safety and immunogenicity.
Strategies to augment Ab responses with adjuvants and
dose-sparing immunization regimens need to be ex-
plored. The second approach will build on basic research
to explore possibilities to induce cross-protective cell-
mediated immunity or Abs to conserved epitopes such
as those on the HA or M2 proteins, but this has a longer
lag time than the first approach.
Acknowledgments
The authors would like to thank Nancy Touchette for helpful discus-
sions and review of the manuscript.
References
Crawford, P.C., Dubovi, E.J., Castleman, W.L., Stephenson, I.,
Gibbs, E.P., Chen, L., Smith, C., Hill, R.C., Ferro, P., Pompey, J.,
et al. (2005). Transmission of equine influenza virus to dogs. Science
310, 482–485.
de Jong, M.D., Tran, T.T., Truong, H.K., Vo, M.H., Smith, G.J.,
Nguyen, V.C., Bach, V.C., Phan, T.Q., Do, Q.H., Guan, Y., et al.
(2005). Oseltamivir resistance during treatment of influenza A
(H5N1) infection. N. Engl. J. Med. 353, 2667–2672.
Epstein, S.L. (2006). Prior H1N1 influenza infection and susceptibility
of Cleveland Family Study participants during the H2N2 pandemic of
1957: An experiment of nature. J. Infect. Dis. 193, 49–53.
Fitch, W.M., Bush, R.M., Bender, C.A., and Cox, N.J. (1997). Long
term trends in the evolution of H(3) HA1 human influenza type A.
Proc. Natl. Acad. Sci. USA 94, 7712–7718.
Hehme, N., Engelmann, H., Kunzel, W., Neumeier, E., and Sanger, R.
(2002). Pandemic preparedness: Lessons learnt from H2N2 and
H9N2 candidate vaccines. Med. Microbiol. Immunol. (Berl.) 191,
203–208.
Le, Q.M., Kiso, M., Someya, K., Sakai, Y.T., Nguyen, T.H., Nguyen,
K.H., Pham, N.D., Ngyen, H.H., Yamada, S., Muramoto, Y., et al.
(2005). Avian flu: Isolation of drug-resistant H5N1 virus. Nature
437, 1108.
Luke, C.J., and Subbarao, K. (2006). Vaccines for pandemic influ-
enza. Emerg. Infect. Dis. 12, 66–72.
Murphy, B.R., and Chanock, R.M. (2001). Immunization against viral
diseases. In Fields Virology, D.M. Knipe, et al., eds. (Philadelphia,
PA: Lippincott, Williams & Wilkins), pp. 435–468.
Neirynck, S., Deroo, T., Saelens, X., Vanlandschoot, P., Jou, W.M.,
and Fiers, W. (1999). A universal influenza A vaccine based on the ex-
tracellular domain of the M2 protein. Nat. Med. 5, 1157–1163.
Nicholson, K.G., Colegate, A.E., Podda, A., Stephenson, I., Wood, J.,
Ypma, E., and Zambon, M.C. (2001). Safety and antigenicity of non-
adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97
(H5N3) vaccine: A randomised trial of two potential vaccines against
H5N1 influenza. Lancet 357, 1937–1943.
Commentary
9Russell, R.J., Gamblin, S.J., Haire, L.F., Stevens, D.J., Xiao, B., Ha,
Y., and Skehel, J.J. (2004). H1 and H7 influenza haemagglutinin
structures extend a structural classification of haemagglutinin sub-
types. Virology 325, 287–296.
Stephenson, I., Nicholson, K.G., Glu¨ck, R., Mischler, R., Newman,
R.W., Palache, A.M., Verlander, N.Q., Warburton, F., Wood, J.M.,
and Zambon, M.C. (2003). Safety and antigenicity of whole virus
and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in
healthy adults: phase I randomised trial. Lancet 362, 1959–1966.
Thompson, W.W., Shay, D.K., Weintraub, E., Brammer, L., Cox, N.,
Anderson, L.J., and Fukuda, K. (2003). Mortality associated with in-
fluenza and respiratory syncytial virus in the United States. JAMA
289, 179–186.
Treanor, J.J., Tierney, E.L., Zebedee, S.L., Lamb, R.A., and Murphy,
B.R. (1990). Passively transferred monoclonal Ab to the M2 protein
inhibits influenza A virus replication in mice. J. Virol. 64, 1375–1377.
Webster, R.G., Bean, W.J., Gorman, O.T., Chambers, T.M., and
Kawaoka, Y. (1992). Evolution and ecology of influenza A viruses.
Microbiol. Rev. 56, 152–179.
Wilson, I.A., and Cox, N.J. (1990). Structural basis of immune recog-
nition of influenza virus hemagglutinin. Annu. Rev. Immunol. 8, 737–
771.
Wright, P.F., and Webster, R.G. (2001). Orthomyxoviruses. In Fields
Virology, D.M. Knipe, et al., eds. (Philadelphia, PA: Lippincott, Wil-
liams & Wilkens), pp. 1533–1580.
